Nonspecific intracellular macromolecules in hypoxic cells

"Nonspecific intracellular macromolecules in hypoxic cells" refers to the diverse array of cellular proteins, nucleic acids, and lipids that become covalently modified by reactive intermediates produced during the bioreduction of hypoxia-activated prodrugs (HAPs) (Wilson & Hay, 2011, Nature Reviews Cancer). In the low-oxygen environment of solid tumors, enzymes such as cytochrome P450 reductase (POR) reduce compounds like nitroimidazoles (e.g., pimonidazole) into reactive radicals or electrophiles (Guise et al., 2014, Frontiers in Pharmacology). In the absence of molecular oxygen—which would otherwise back-oxidize these intermediates—the reactive species form stable, irreversible adducts with nearby macromolecules (Raleigh et al., 1998, British Journal of Cancer). This process is exploited in oncology for both therapeutic purposes, to selectively kill hypoxic cells, and for diagnostic imaging to map tumor oxygenation levels (Brown, 1993, Molecular Medicine Today). Because this "target" encompasses a broad spectrum of cellular constituents rather than a specific protein or receptor, it represents a chemical trapping mechanism rather than a traditional molecular target (Koch, 2002, Methods in Enzymology). Consequently, while these macromolecules are essential for the localization and efficacy of HAPs, they do not constitute a specific molecular entity in the standard pharmacological sense (Dische, 1989, International Journal of Radiation Oncology*Biology*Physics).

Other names

Hypoxic cell adductsIntracellular protein and DNA adductsBioreductive drug substratesHypoxia-activated prodrug binding sites

Hypoxia-activated prodrugs are enzymatically reduced to reactive intermediates that, in the absence of oxygen, form covalent adducts with intracellular macromolecules, leading to drug entrapment and localized cytotoxicity (Wilson & Hay, 2011).